For Q3 FY2024 (ended September 30, 2024), Contineum Therapeutics reported zero revenue and a net loss of $14.5 million, with diluted EPS of -$0.39. Operating loss was $16.9 million. The company had no cash, equity, or long-term debt disclosed.
•Revenue was $0 for the quarter.
•Net loss of $14.5 million, with diluted EPS of -$0.39.
•Operating loss of $16.9 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company develops of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.
The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis.
Formerly known as Pipeline Therapeutics, Inc., the company rebranded as Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing small molecule therapies for neuroscience, inflammation, and immunology indications. Its lead asset is PIPE-791, a brain-penetrant small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R), being developed for idiopathic pulmonary fibrosis and chronic pain. The company also has PIPE-307, a small-molecule inhibitor of the muscarinic type 1 receptor, targeting depression and relapsing-remitting multiple sclerosis. Contineum Therapeutics is based in San Diego, California, and was incorporated in 2009. It was formerly known as Pipeline Therapeutics, Inc. before rebranding in November 2023.
Where is Contineum Therapeutics (CTNM) listed and in what currency?
Contineum Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CTNM. The company trades in U.S. dollars (USD), as it is headquartered in the United States. The exchange is one of the major U.S. stock exchanges, providing liquidity and visibility for investors. The listing on NasdaqGS indicates that the company meets stringent financial and governance standards. Investors can trade CTNM shares during regular market hours, and the stock is denominated in USD, which is the official currency of the United States.
What sector and industry does Contineum Therapeutics belong to?
Contineum Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical stage biopharmaceutical company, it focuses on developing innovative small molecule therapies for serious medical conditions. The biotechnology industry involves using biological processes and organisms to develop drugs and treatments, and Contineum's work in neuroscience, inflammation, and immunology places it at the intersection of several therapeutic areas. The company's pipeline includes candidates for idiopathic pulmonary fibrosis, chronic pain, depression, and multiple sclerosis, reflecting its commitment to addressing unmet medical needs in these fields.
Where is Contineum Therapeutics headquartered and what is its history?
Contineum Therapeutics, Inc. is headquartered in San Diego, California, United States. The company was incorporated in 2009 and was originally known as Pipeline Therapeutics, Inc. In November 2023, it rebranded to Contineum Therapeutics, Inc. The San Diego location places it within a major biotech hub, providing access to talent and research resources. The company's history spans over a decade, during which it has advanced its pipeline of small molecule therapies. The rebranding in 2023 may reflect a strategic shift or evolution in its focus areas, but the core mission of developing treatments for neuroscience, inflammation, and immunology indications remains unchanged.
What are the main drug candidates in Contineum Therapeutics' pipeline?
Contineum Therapeutics has two main drug candidates. The lead asset is PIPE-791, a novel, brain-penetrant small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R). It is being developed for idiopathic pulmonary fibrosis (IPF), a chronic lung disease, and chronic pain. The second candidate is PIPE-307, a small-molecule inhibitor of the muscarinic type 1 receptor, targeting depression and relapsing-remitting multiple sclerosis (RRMS). Both candidates are in clinical development, and the company focuses on small molecule therapies that can cross the blood-brain barrier. These programs address significant unmet medical needs in neuroscience and inflammation, with potential to improve patient outcomes.